Bayer HealthCare / News archive

News archive

Topic
Product
Date
2014-11-18
Bayer Receives Approval for EYLEA® in Diabetic Macular Edema in Japan

Bayer Receives Approval for EYLEA® in Diabetic Macular Edema in Japan #

Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for EYLEA® (aflibercept solution for injection) for the treatment of patients with diabetic macular edema (DME).   » more

2014-11-17

Bayer increases its donations of medications for ebola patients

Bayer is expanding its aid donations for ebola patients in Liberia and Sierra Leone. The company is supplementing its previous donation of medications with a further delivery of the antibiotic ciprofloxacin to a value of EUR 1.15 million. This medication does not treat the ebola infection itself, but can be used for life-threatening secondary bacterial infections.   » more

2014-11-13
Bayer to Evaluate sGC Stimulator Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis

Bayer to Evaluate sGC Stimulator Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis #

The development of riociguat in dcSSc is part of the recently announced worldwide strategic collaboration with Merck & Co., Inc. (known as MSD outside of the U.S. and Canada) in the field of soluble guanylate cyclase (sGC) modulation.   » more

2014-11-10

New Clinical and Real-World Data to Provide Further Insights on the Utility of Bayer’s Xarelto® for Patients with Atrial Fibrillation #

Bayer HealthCare announced today that new data from clinical trials and real-world studies to be presented at the American Heart Association (AHA) Scientific Sessions 2014 in Chicago, Il, USA, November 15-19, 2014, will provide important insights regarding the clinical utility of its novel oral anticoagulant Xarelto® (rivaroxaban) for stroke prevention in patients with atrial fibrillation (AF).   » more

2014-11-03
Bayer HealthCare to invest up to USD 25 million in “Versant Venture Capital V” fund

Bayer HealthCare to invest up to USD 25 million in “Versant Venture Capital V” fund

Bayer and Versant Ventures have already joined forces in ophthalmology research. In November 2013, Bayer HealthCare announced an exclusive collaboration with Inception Sciences - a drug discovery incubator exclusively backed by Versant Ventures - to conduct early research in the area of retinal eye diseases.   » more

2014-11-03

Bayer completes acquisition of Dihon Pharmaceutical Group Co., Ltd. in China

Bayer has completed the acquisition of 100 percent of the shares of Dihon Pharmaceutical Group Co., Ltd., Kunming, Yunnan, China, a privately held pharmaceutical company specializing primarily in over-the-counter (OTC) dermatology products and herbal traditional Chinese medicine (TCM) products for various women’s health indications.   » more

2014-10-30

Bayer operationally strong – strategic focus on Life Science businesses

The Bayer Group continued its successful business development. “The strong upward trend in the Life Science businesses – HealthCare and CropScience – persisted in the third quarter.   » more

2014-10-24
Bayer Forms Alliance with Kyoto University in Japan

Bayer Forms Alliance with Kyoto University in Japan

This collaboration is part of Bayer’s overall approach to partner with external partners from academia and industry to discover and develop new treatment options for patients worldwide.   » more

2014-10-13
Bayer Supports World Thrombosis Day as Founding Global Partner

Bayer Supports World Thrombosis Day as Founding Global Partner

As founding global partner, Bayer HealthCare joins the International Society on Thrombosis and Haemostasis (ISTH) today to launch the annual World Thrombosis Day.   » more

2014-10-01

Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion

Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals.   » more

2014-09-26
Bayer Supports World Contraception Day to Help Young People Build Awareness for Contraception

Bayer Supports World Contraception Day to Help Young People Build Awareness for Contraception

On the occasion of today’s World Contraception Day (WCD), Bayer supports the publication of the WCD Coalition “Framework for Action” plan calling on individuals, governments and organizations to address the alarming number of unplanned pregnancies and sexually transmitted infections (STIs) worldwide.   » more

2014-09-24

ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise #

Bayer HealthCare announced today that data from its oncology portfolio, including Stivarga® (regorafenib) tablets, Nexavar® (sorafenib) tablets and Xofigo® (radium Ra 223 dichloride) injection, will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress taking place September 26 – 30 in Madrid, Spain.   » more

2014-09-22
Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan

Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan #

The approval is based on positive data from the Phase 3 MYRROR study in myopic CNV. The topline results, where patients receiving EYLEA had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of 12.1 letters, compared to a loss of 2 letters in patients receiving sham injections ( p<0.0001), were announced at the American Academy of Ophthalmology Congress in New Orleans.   » more

2014-09-16
Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer #

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational novel oral androgen receptor (AR) inhibitor in clinical development for the treatment of patients with prostate cancer.   » more

2014-09-08
Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies

Safety and Sustained Benefits of Adempas® From Bayer Confirmed by Results of Long-Term Studies #

Riociguat is a soluble guanylate cyclase (sGC) stimulator, the first member of a novel class of compounds to target a key molecular mechanism underlying pulmonary hypertension (PH).   » more

2014-09-04

Bayer Submits New Application for Aflibercept Solution for Injection into the Eye in Japan Based on Phase 3 Data in Patients with BRVO #

Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for aflibercept solution for injection into the eye, based on the Phase 3 VIBRANT trial in patients with macular edema secondary to branch retinal vein occlusion (BRVO).   » more

2014-09-02

Bayer closes on divestiture of Interventional device business to Boston Scientific

Bayer HealthCare closed on the divestiture of its Interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is USD 415 million (about EUR 300 million).   » more

2014-09-02
Once-Daily Xarelto® from Bayer Effective and Well-Tolerated Alternative to Vitamin K Antagonists in Protecting Patients with Atrial Fibrillation who Undergo Cardioversion

Once-Daily Xarelto® from Bayer Effective and Well-Tolerated Alternative to Vitamin K Antagonists in Protecting Patients with Atrial Fibrillation who Undergo Cardioversion #

Bayer HealthCare today announced results from the X-VeRT study demonstrating that once-daily Xarelto® (rivaroxaban) is an effective and well-tolerated alternative to dose-adjusted vitamin K antagonists (VKAs) such as warfarin in patients with non-valvular atrial fibrillation undergoing cardioversion.   » more

2014-08-29
Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism #

Bayer HealthCare and its development partner Janssen Research & Development, LLC announced today an expansion of the global clinical development programme for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism.   » more

2014-08-25
New Data on Xarelto® (Rivaroxaban) from Bayer accepted for ESC Congress 2014 Hot Line Session

New Data on Xarelto® (Rivaroxaban) from Bayer accepted for ESC Congress 2014 Hot Line Session #

Bayer HealthCare announced today that results from the Phase IIIb exploratory X-VeRT study investigating the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in patients with non-valvular atrial fibrillation (AF) undergoing elective cardioversion will be presented in a Hot Line Session during the upcoming ESC Congress 2014 in Barcelona, Spain, August 30 - September 3, 2014.   » more

2014-08-11
Bayer Receives EU Approval for EYLEA® in Diabetic Macular Edema

Bayer Receives EU Approval for EYLEA® in Diabetic Macular Edema #

Bayer HealthCare announced today that EYLEA® (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular edema (DME). Bayer plans for an immediate roll-out with Germany being one of the first launch countries in Europe.   » more

2014-07-30

Bayer continues positive business development

The Bayer Group was again successful in the second quarter of 2014. "Our Life Science businesses, in particular, saw unabated growth momentum, with very encouraging sales gains for our recently launched pharmaceutical products and our North and Latin American CropScience business," said Management Board Chairman Dr. Marijn Dekkers when the interim report was published on Wednesday.   » more

2014-07-30
Stivarga® (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors

Stivarga® (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors #

Approval in the second indication for Stivarga in the EU within one year / Decision based on positive results from Phase III GRID trial in which regorafenib significantly extended progression-free survival   » more

2014-07-30
Aflibercept Solution for Injection into the Eye Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)

Aflibercept Solution for Injection into the Eye Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME) #

The approval of aflibercept solution for injection in DME was based on the one year data from the Phase 3 VISTA-DME and VIVID-DME trials of 862 patients, which compared aflibercept solution for injection 2 milligrams (mg) given monthly, 2 mg given every two months (after five initial monthly injections), or macular laser photocoagulation (at baseline and then as needed).   » more

2014-07-25

Phase III Trial of Sorafenib in Combination with Capecitabine Does Not Meet Primary Endpoint in Patients with Advanced Breast Cancer #

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that an investigational Phase III trial of sorafenib (Nexavar®) tablets plus capecitabine in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).   » more

2014-07-18
Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema

Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema #

Full two-year data from the VIVID-DME trial will be presented at upcoming medical conferences. Both the VIVID-DME and the VISTA-DME trials will continue as planned up to 148 weeks.   » more

2014-07-03
Bayer and University of Oxford to Develop Novel Gynecological Therapies

Bayer and University of Oxford to Develop Novel Gynecological Therapies

Under the terms of the agreement both parties will contribute innovative drug targets and high quality technology infrastructures. Furthermore, Bayer and the University of Oxford will share responsibilities from basic research to early clinical trials in these two diseases.   » more

2014-06-27
Regorafenib from Bayer Recommended for Approval in the European Union for the Treatment of Gastrointestinal Stromal Tumors

Regorafenib from Bayer Recommended for Approval in the European Union for the Treatment of Gastrointestinal Stromal Tumors #

The oncology compound regorafenib (Stivarga®) from Bayer has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.   » more

2014-06-27
Bayer Receives positive CHMP Opinion for the Treatment of Visual Impairment due to Diabetic Macular Edema in EU

Bayer Receives positive CHMP Opinion for the Treatment of Visual Impairment due to Diabetic Macular Edema in EU #

The final decision of the European Commission is expected in the coming months.   » more

2014-06-23
Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A

Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A

Depending on the results of the Phase I/IIa clinical trial, Bayer will conduct the confirmatory Phase III trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of hemophilia A. Dimension Therapeutics is eligible to receive tiered royalties based on product sales.   » more

You see the news 1 to 30 out of 408
1 2 3 4 5 6 7 8 9 10 Next >
Bayer HealthCare Links

Annual report Integrated Annual Report of Bayer AG 2013
RSS Feed
RSS Feed

http://press.healthcare.bayer.com/en/press/news/news-archive/index.php

Copyright © Bayer HealthCare AG